Neuroscience Research

Dr. Francesco Neri of NeuroAge Therapeutics describes how he’s using Revvity’s Operetta CLS™ high-content analysis system to study neurodegenerative disorders.

Explore how brain-on-chip models are advancing Alzheimer’s research by targeting toxic amyloid-beta oligomers in ETAP-Lab’s latest preclinical work.

The article discusses the role of α-Synuclein in Parkinson’s disease and other synucleinopathies, highlighting the challenges in detecting this protein at low levels. It introduces an innovative approach using AlphaLISA™ SureFire® Ultra™ assays to measure total and phosphorylated α-Synuclein in complex matrices, along with BioLegend's LEGEND MAX α-Synuclein Aggregate ELISA kit to quantify aggregated levels in brain tissue from PFF-inoculated and sham-treated mice.

The complexity of neurodegenerative diseases, and the associated challenges of modelling the development and function of the human brain, have made many disorders difficult to study experimentally.

Around 50 million people worldwide currently suffer from one or more forms of dementia. Of these, around 850,000 live in the United Kingdom (UK) at an annual care cost of £26 billion (US$38 billion)

Recent research shows that microRNAs (miRNAs), small RNAs with functions beyond protein translation, are abundant in the central nervous system.

To accelerate their discovery of new treatments for Huntington’s disease (HD), researchers at the University College of London developed a human neuronal cell model of the disease for use in high-throughput screening of potential therapies.

In recent years, the therapeutic potential of ribonucleic acid (RNA) has been thrust into the spotlight, with research in this area now thriving. Several RNA-based therapies have been authorized and approved – including some of the first COVID-19 vaccines – and many more are currently in the pipeline.